Safety and Efficacy of Influenza Vaccination in Patients Receiving Immune Checkpoint Inhibitors. Systematic Review with Meta-Analysis
| العنوان: | Safety and Efficacy of Influenza Vaccination in Patients Receiving Immune Checkpoint Inhibitors. Systematic Review with Meta-Analysis |
|---|---|
| المؤلفون: | Maria A. Lopez-Olivo, Valeria Valerio, Aliza R. Karpes Matusevich, Marianela Brizio, Michelle Kwok, Yimin Geng, Maria E. Suarez-Almazor, Ines Colmegna |
| المصدر: | Vaccines. 10:1195 |
| بيانات النشر: | MDPI AG, 2022. |
| سنة النشر: | 2022 |
| مصطلحات موضوعية: | Pharmacology, Infectious Diseases, Drug Discovery, Immunology, Pharmacology (medical) |
| الوصف: | The potential increased risk of immune-related adverse events (irAEs) post-influenza vaccine is a concern in patients receiving immune checkpoint inhibitors (ICI). We conducted a systematic review with meta-analysis of studies reporting the effects of influenza vaccination in patients with cancer during ICI treatment. We searched five electronic databases until 01/2022. Two authors independently selected studies, appraised their quality, and collected data. The primary outcome was the determination of pooled irAE rates. Secondary outcomes included determination of immunogenicity and influenza infection rates and cancer-related outcomes. Nineteen studies (26 publications, n = 4705) were included; 89.5% were observational. Vaccinated patients reported slighter lower rates of irAEs compared to unvaccinated patients (32% versus 41%, respectively). Seroprotection for influenza type A was 78%–79%, and for type B was 75%. Influenza and irAE-related death rates were similar between groups. The pooled proportion of participants reporting a laboratory-confirmed infection was 2% (95% CI 0% to 6%), and influenza-like illness was 14% (95% CI 2% to 32%). No differences were reported on the rates of laboratory-confirmed infection between vaccinated and unvaccinated patients. Longer progression-free and overall survival was also observed in vaccinated compared with unvaccinated patients. Current evidence suggests that influenza vaccination is safe in patients receiving ICIs, does not increase the risk of irAEs, and may improve survival. |
| تدمد: | 2076-393X |
| الوصول الحر: | https://explore.openaire.eu/search/publication?articleId=doi_dedup___::4b221f19e469b38e7791ae607c566cbaTest https://doi.org/10.3390/vaccines10081195Test |
| حقوق: | OPEN |
| رقم الانضمام: | edsair.doi.dedup.....4b221f19e469b38e7791ae607c566cba |
| قاعدة البيانات: | OpenAIRE |
| ResultId |
1 |
|---|---|
| Header |
edsair OpenAIRE edsair.doi.dedup.....4b221f19e469b38e7791ae607c566cba 862 3 unknown 861.729675292969 |
| PLink |
https://search.ebscohost.com/login.aspx?direct=true&site=eds-live&scope=site&db=edsair&AN=edsair.doi.dedup.....4b221f19e469b38e7791ae607c566cba&custid=s6537998&authtype=sso |
| FullText |
Array
(
[Availability] => 0
)
|
| Items |
Array
(
[Name] => Title
[Label] => Title
[Group] => Ti
[Data] => Safety and Efficacy of Influenza Vaccination in Patients Receiving Immune Checkpoint Inhibitors. Systematic Review with Meta-Analysis
)
Array ( [Name] => Author [Label] => Authors [Group] => Au [Data] => <searchLink fieldCode="AR" term="%22Maria+A%2E+Lopez-Olivo%22">Maria A. Lopez-Olivo</searchLink><br /><searchLink fieldCode="AR" term="%22Valeria+Valerio%22">Valeria Valerio</searchLink><br /><searchLink fieldCode="AR" term="%22Aliza+R%2E+Karpes+Matusevich%22">Aliza R. Karpes Matusevich</searchLink><br /><searchLink fieldCode="AR" term="%22Marianela+Brizio%22">Marianela Brizio</searchLink><br /><searchLink fieldCode="AR" term="%22Michelle+Kwok%22">Michelle Kwok</searchLink><br /><searchLink fieldCode="AR" term="%22Yimin+Geng%22">Yimin Geng</searchLink><br /><searchLink fieldCode="AR" term="%22Maria+E%2E+Suarez-Almazor%22">Maria E. Suarez-Almazor</searchLink><br /><searchLink fieldCode="AR" term="%22Ines+Colmegna%22">Ines Colmegna</searchLink> ) Array ( [Name] => TitleSource [Label] => Source [Group] => Src [Data] => <i>Vaccines</i>. 10:1195 ) Array ( [Name] => Publisher [Label] => Publisher Information [Group] => PubInfo [Data] => MDPI AG, 2022. ) Array ( [Name] => DatePubCY [Label] => Publication Year [Group] => Date [Data] => 2022 ) Array ( [Name] => Subject [Label] => Subject Terms [Group] => Su [Data] => <searchLink fieldCode="DE" term="%22Pharmacology%22">Pharmacology</searchLink><br /><searchLink fieldCode="DE" term="%22Infectious+Diseases%22">Infectious Diseases</searchLink><br /><searchLink fieldCode="DE" term="%22Drug+Discovery%22">Drug Discovery</searchLink><br /><searchLink fieldCode="DE" term="%22Immunology%22">Immunology</searchLink><br /><searchLink fieldCode="DE" term="%22Pharmacology+%28medical%29%22">Pharmacology (medical)</searchLink> ) Array ( [Name] => Abstract [Label] => Description [Group] => Ab [Data] => The potential increased risk of immune-related adverse events (irAEs) post-influenza vaccine is a concern in patients receiving immune checkpoint inhibitors (ICI). We conducted a systematic review with meta-analysis of studies reporting the effects of influenza vaccination in patients with cancer during ICI treatment. We searched five electronic databases until 01/2022. Two authors independently selected studies, appraised their quality, and collected data. The primary outcome was the determination of pooled irAE rates. Secondary outcomes included determination of immunogenicity and influenza infection rates and cancer-related outcomes. Nineteen studies (26 publications, n = 4705) were included; 89.5% were observational. Vaccinated patients reported slighter lower rates of irAEs compared to unvaccinated patients (32% versus 41%, respectively). Seroprotection for influenza type A was 78%–79%, and for type B was 75%. Influenza and irAE-related death rates were similar between groups. The pooled proportion of participants reporting a laboratory-confirmed infection was 2% (95% CI 0% to 6%), and influenza-like illness was 14% (95% CI 2% to 32%). No differences were reported on the rates of laboratory-confirmed infection between vaccinated and unvaccinated patients. Longer progression-free and overall survival was also observed in vaccinated compared with unvaccinated patients. Current evidence suggests that influenza vaccination is safe in patients receiving ICIs, does not increase the risk of irAEs, and may improve survival. ) Array ( [Name] => ISSN [Label] => ISSN [Group] => ISSN [Data] => 2076-393X ) Array ( [Name] => URL [Label] => Access URL [Group] => URL [Data] => <link linkTarget="URL" linkTerm="https://explore.openaire.eu/search/publication?articleId=doi_dedup___::4b221f19e469b38e7791ae607c566cba" linkWindow="_blank">https://explore.openaire.eu/search/publication?articleId=doi_dedup___::4b221f19e469b38e7791ae607c566cba</link><br /><link linkTarget="URL" linkTerm="https://doi.org/10.3390/vaccines10081195" linkWindow="_blank">https://doi.org/10.3390/vaccines10081195</link> ) Array ( [Name] => Copyright [Label] => Rights [Group] => Cpyrght [Data] => OPEN ) Array ( [Name] => AN [Label] => Accession Number [Group] => ID [Data] => edsair.doi.dedup.....4b221f19e469b38e7791ae607c566cba ) |
| RecordInfo |
Array
(
[BibEntity] => Array
(
[Languages] => Array
(
[0] => Array
(
[Text] => Undetermined
)
)
[PhysicalDescription] => Array
(
[Pagination] => Array
(
[PageCount] => 1
[StartPage] => 1195
)
)
[Subjects] => Array
(
[0] => Array
(
[SubjectFull] => Pharmacology
[Type] => general
)
[1] => Array
(
[SubjectFull] => Infectious Diseases
[Type] => general
)
[2] => Array
(
[SubjectFull] => Drug Discovery
[Type] => general
)
[3] => Array
(
[SubjectFull] => Immunology
[Type] => general
)
[4] => Array
(
[SubjectFull] => Pharmacology (medical)
[Type] => general
)
)
[Titles] => Array
(
[0] => Array
(
[TitleFull] => Safety and Efficacy of Influenza Vaccination in Patients Receiving Immune Checkpoint Inhibitors. Systematic Review with Meta-Analysis
[Type] => main
)
)
)
[BibRelationships] => Array
(
[HasContributorRelationships] => Array
(
[0] => Array
(
[PersonEntity] => Array
(
[Name] => Array
(
[NameFull] => Maria A. Lopez-Olivo
)
)
)
[1] => Array
(
[PersonEntity] => Array
(
[Name] => Array
(
[NameFull] => Valeria Valerio
)
)
)
[2] => Array
(
[PersonEntity] => Array
(
[Name] => Array
(
[NameFull] => Aliza R. Karpes Matusevich
)
)
)
[3] => Array
(
[PersonEntity] => Array
(
[Name] => Array
(
[NameFull] => Marianela Brizio
)
)
)
[4] => Array
(
[PersonEntity] => Array
(
[Name] => Array
(
[NameFull] => Michelle Kwok
)
)
)
[5] => Array
(
[PersonEntity] => Array
(
[Name] => Array
(
[NameFull] => Yimin Geng
)
)
)
[6] => Array
(
[PersonEntity] => Array
(
[Name] => Array
(
[NameFull] => Maria E. Suarez-Almazor
)
)
)
[7] => Array
(
[PersonEntity] => Array
(
[Name] => Array
(
[NameFull] => Ines Colmegna
)
)
)
)
[IsPartOfRelationships] => Array
(
[0] => Array
(
[BibEntity] => Array
(
[Dates] => Array
(
[0] => Array
(
[D] => 27
[M] => 07
[Type] => published
[Y] => 2022
)
)
[Identifiers] => Array
(
[0] => Array
(
[Type] => issn-print
[Value] => 2076393X
)
[1] => Array
(
[Type] => issn-locals
[Value] => edsair
)
[2] => Array
(
[Type] => issn-locals
[Value] => edsairFT
)
)
[Numbering] => Array
(
[0] => Array
(
[Type] => volume
[Value] => 10
)
)
[Titles] => Array
(
[0] => Array
(
[TitleFull] => Vaccines
[Type] => main
)
)
)
)
)
)
)
|
| IllustrationInfo |